Fidelity Management & Research Co. recently announced the acquisition of new stake in Sage Therapeutics Inc. (NASDAQ:SAGE). The institutional investor has increased its shareholding in the Healthcare company by 0.14% to 7.72 million shares with purchase of 10539.0 shares. This fresh investment now brings its stake to 14.88% valued currently at $275.9 million. In addition, The Vanguard Group, Inc. raised its holdings by 93456.0 to 4.75 million shares. And Great Point Partners LLC has lifted its position by 129.19% or 1.03 million shares – to 1.82 million shares.
With over 0.55 million Sage Therapeutics Inc. (SAGE) shares trading Friday and a closing price of $42.92 on the day, the dollar volume was approximately $23.42 million. The shares have shown a negative weekly performance of -0.21% and its price on 07/10/20 lost nearly -2.70%. Currently, there are 51.91M common shares owned by the public and among those 50.95M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 21 analysts who have offered their price forecasts for SAGE have a consensus price objective of $74.50. The analysts have set the share’s price value over the next 12 months at a high of $190.00 and a low of $35.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Sage Therapeutics Inc. stock is 2.00 for the next 12 months. The average price target is 41.91% above its last price level and an upside to the estimated low will see the stock lose -22.63% over that period. But an upside of 77.41% will see the stock hit the forecast high price target while mean target price for the stock is $70.50.
Insiders at the company have transacted a total of 28 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 20 of these insider trades were purchases, accounting for 134,393 shares. Insider sales of the common stock occurred on 8 occasions, with total insider shares sold totaling 14,762 shares.
The top 3 mutual fund holders in Sage Therapeutics Inc. are Fidelity Growth Company Fund, American Funds Growth Fund of Ame, and Vanguard Total Stock Market Index. Fidelity Growth Company Fund owns 2.49 million shares of the company’s stock, all valued at over $89.03 million. The company bought an additional 0.11 million shares recently to bring their total holdings to about 4.80% of the shares outstanding. American Funds Growth Fund of Ame bought 0.12 million shares to see its total holdings expand to 2.01 million shares valued at over $71.84 million and representing 3.87% of the shares outstanding. Vanguard Total Stock Market Index sold 1092.0 shares to bring its total holdings to over 1.5 million shares at a value of $53.55 million. Vanguard Total Stock Market Index now owns shares totaling to 2.89% of the shares outstanding.
Shares of Sage Therapeutics Inc. (NASDAQ: SAGE) opened at $44.33, up $0.22 from a prior closing price of $44.11. However, the script later closed the day at $42.92, down -2.70%. The company’s stock has a 5-day price change of -0.21% and 47.85% over the past three months. SAGE shares are trading -40.55% year to date (YTD), with the 12-month market performance down to -77.37% lower. It has a 12-month low price of $25.01 and touched a high of $193.56 over the same period. Currently, 0.55 million shares have been traded, compared to an average intraday trading volume of 1.05 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 4.91%, 10.34%, and -41.78% respectively.
Institutional ownership of Sage Therapeutics Inc. (NASDAQ: SAGE) 51.91M shares outstanding. Mutual fund holders own 46.01%, while other institutional holders and individual stakeholders account for 60.38% and 4.79% respectively.
It has a market capitalization of $2.25B and a beta (3y monthly) value of 2.69. The earnings-per-share (ttm) stands at -$12.46. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.65% over the week and 5.29% over the month.
Analysts forecast that Sage Therapeutics Inc. (SAGE) will achieve an EPS of -$2.66 for the current quarter, -$2.38 for the next quarter and -$9.19 for 2021. The lowest estimate earnings-per-share for the quarter is -$3.12 while analysts give the company a high EPS estimate of -$1.9. Comparatively, EPS for the current quarter was -$3.28 a year ago. Earnings per share for the fiscal year are expected to decrease by -65.50%, and 8.20% over the next financial year. EPS should grow at an annualized rate of 13.10% over the next five years, compared to -51.60% over the past 5-year period.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 21 brokerage firm advisors rate Sage Therapeutics Inc. (SAGE) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 13 Wall Street analysts polled rate the stock as a buy, while 8 of the 21 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the SAGE, a number of firms have released research notes about the stock. Wedbush stated their Neutral rating for the stock in a research note on May 08, 2020, with the firm’s price target at. Guggenheim coverage for the Sage Therapeutics Inc. (SAGE) stock in a research note released on April 08, 2020 offered a Neutral rating with a price target of. RBC Capital Mkts was of a view on March 18, 2020 that the stock is Outperform, while Citigroup gave the stock Buy rating on March 06, 2020, issuing a price target of $71. H.C. Wainwright on their part issued Neutral rating on February 28, 2020.